Previous 10 | Next 10 |
home / stock / hnsbf / hnsbf news
Hansa Biopharma AB ( OTC:HNSBF ): Q2 GAAP EPS of -SEK2.06. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...
MALMÖ, Sweden , July 18, 2019 /PRNewswire/ -- Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome (GBS) continues. Highlights for the second quarter 2019 - At the 2019 American...
LUND, Sweden , June 7, 2019 /PRNewswire/ -- Hansa Biopharma AB ("Hansa") (NASDAQ Stockholm: HNSA ), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIXTM (imlifidase), the company's novel IgG-degrading enzyme, was highlighted in ...
LUND, Sweden , May 13, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences...
LUND, Sweden , May 2, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that IDEFIRIX (imlifidase), the Company's novel IgG-degrading enzyme, will be highlighted in three prese...
Hansa Biopharma AB ( OTC:HNSBF ): Q1 GAAP EPS of -SEK1.81. More news on: Hansa Biopharma AB, Earnings news and commentary, Read more ...
MALMÖ, Sweden , April 17, 2019 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund , summons to Annual General Meeting on Wednesday 22 Maj 2019 at 17.00 CEST at the auditorium next to the company's premises, Scheelevägen 22, Lund, S...
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...